This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Anavekar, N. S Articles by Solomon, S. D Search for Related Content PubMed PubMed Citation Articles by Anavekar, N. S Articles by Solomon, S. D Social Bookmarking                         What's this?

Angiotensin II receptor blockade and ventricular remodelling

Wynn Metabolic Cardiology Unit, Baker Heart Institute, Melbourne, Australia

Scott D Solomon

Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, USA, ssolomon{at}rics.bwh.harvard.edu

Cardiac remodelling is the expression of molecular, cellular and interstitial changes in response to cardiac injury, manifesting as adverse alterations in the size, shape and function of the ventricle. Several clinical studies have documented significant elevations in the levels of renin, angiotensin II (Ang II) and aldosterone attending acute myocardial infarction and/or congestive heart failure. Similar to catecholamines, markedly elevated activity of the renin-angiotensin-aldosterone system (RAAS) is associated with poor prognosis. The effects of Ang II upon cardiac tissue are related to two primary receptors, Ang II type 1 (AT ₁₎ and Ang II type 2 (AT₂). The AT₁-receptor appears to mediate many of the deleterious effects of chronic RAAS activity, while the AT₂-receptor is increasingly shown to have potential cardioprotective effects. Attenuating the deleterious effects of sustained Ang II stimulation can be achieved by direct inhibition of angiotensin-converting enzyme (ACE) and/or direct antagonism of AT receptors. ACE inhibition reduces left ventricular (LV) volumes, retards the progression of LV dilatation and hypertrophy and increases systolic function in systolic dysfunction. By blocking at the receptor level, Ang II receptor blockers (ARBs) provide an alternative and more direct approach to inhibiting the effects of Ang II; however, data relating to their effects upon ventricular remodelling, whether used in isolation or in combination with ACE inhibitors (ACE-Is), are less convincing. Data arising from several recent clinical trials suggest that simultaneous use of ACE-Is and ARBs maybe of more benefit in attenuating ventricular remodelling than either agent alone.

Key Words: remodelling • angiotensin receptor blockers • ACE inhibitors • ventricle • angiotensin II • clinical trials

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 1, 43-48 (2005)
DOI: 10.3317/jraas.2005.006


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Verdecchia, P. Sleight, G. Mancia, R. Fagard, B. Trimarco, R. E. Schmieder, J.-H. Kim, G. Jennings, P. Jansky, J.-H. Chen, et al. Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease Circulation, October 6, 2009; 120(14): 1380 - 1389. [Abstract] [Full Text] [PDF]